Wednesday 19th March - Main Conference Day OneWednesday, 19 March 2025 - PT (Pacific Time, GMT-08:00)

The biopharmaceutical industry faces increasing pressure to produce a wide range of therapeutics quickly, with high yields and consistent quality. Lonza helps companies meet these demands with integrated solutions that streamline the entire drug development process. By combining cutting-edge expression technology, efficient CHO media systems, and expert biologics services, we support drug developers and producers from late-stage discovery all the way to commercial supply.

At the core of our solutions is the proven GS® platform, designed to deliver high-yield, scalable, and stable expression for a broad range of biotherapeutics. With this platform, we help you optimize the expression of your molecule, whatever its type, helping to reduce time to market.

Supporting this, the TheraPRO® CHO Media System offers a chemically defined, non-animal origin (NAO) formulation, solution engineered to maximize protein yield and ensure scalability across research and manufacturing stages. Its advanced formulation delivers consistent performance and simplifies workflows, backed by proven performance for modern bioprocessing needs.

Lonza’s biologics services further offer end-to-end solutions for any molecule type. These services encompass drug candidate selection & optimization, process development, clinical and commercial manufacturing, and regulatory support, helping customers reach the clinic and market faster.

In this talk, we'll cover how our proven GS® platform, CHO media, and expertise in biologics enable biopharmaceutical companies to efficiently bring scalable, high-quality therapies to market, transforming scientific innovation into life-changing treatments for patients.

• Strategies To Balancing Chain Ratio and Assembly Issues To Maximise Formation of Fully Formed Multispecifics;
• Solutions for preventing light chain swapping;
• Analytical techniques to screen and ensure proper chain pairing;
• Case studies on successful mitigation of chain mismatching issues;
• Can transposons give a better ratio?
• Vector design strategies? Promoters? - Explore innovative strategies for optimizing expression vectors, with a focus on chain ratio modulation;
• Keep product impurities to a minimum;
• Strategies to navigate longer timelines and additional assays required for multispecifics;
• How to reduce aggregation of product within the cell? Bioreactor conditions? Engineering?

Cas-CLOVER is an advanced alternative to CRISPR/Cas9 that provides numerous technical and commercial benefits. Notable advantages include enhanced targeted integration efficiency, larger transgene cargo capacity, and superior commercial freedom to operate (FTO) profiles within CRISPR-based genome editing.

The targeted integration strategies employed by Cas-CLOVER for cell line development (CLD) offer significant benefits compared to plasmid or transposase delivery systems. Unlike CRISPR/Cas9, which exhibits low knock-in efficiency and restricted transgene size delivery capacity, Cas-CLOVER addresses these limitations. The suboptimal outcomes associated with CRISPR/Cas9 may be attributed to its blunt-ended cutting mechanism and/or monomeric nature, which lead to undesirable off-target effects and translational inconsistencies.

Our data demonstrates that Cas-CLOVER, leveraging an enhanced dimeric CRISPR-based system and the proprietary nuclease Clo051, achieves threefold higher targeted knock-in efficiencies and supports transgene cargo capacities of at least 20 kb. This evidence underscores Cas-CLOVER's potential to transform CLD, enabling the expression of complex molecules, including bi- and tri-specific antibodies, with greater precision and efficiency.